Isabelle Billet - Axogen Chief Strategy and Business Development Officer
| AXGN Stock | USD 18.97 0.88 4.86% |
Executive
Ms. Isabelle Billet serves as Chief Strategy and Business Development Officer of the company. From July 2013 until joining Axogen as Chief Strategy and Business Development Officer, Ms. Billet worked for IBHC Advisors LLC, a consulting firm she founded which assisted medical device companies in their organic and inorganic growth strategies and supported private equity firms on their investment strategy and due diligence. From 2010 to 2013, Ms. Billet worked at Cardinal Health, Inc where she served as Senior Vice President of Marketing and Innovation for the Medical segment focusing on their private brand portfolio development. From 2005 to 2010, she was Vice President Marketing and New Business Development for C.R. Bard Medical division. She worked for Johnson and Johnson from 1992 to 2005, splitting her tenure between Advanced Sterilization Products and Ethicon, Inc in positions of increasing responsibilities in marketing and new business development in France, Europe and US. Ms. Billet spent the first 7 years of her career as the head pharmacist and material manager for a private hospital in France since 2018.
| Age | 62 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 13631 Progress Boulevard, Alachua, FL, United States, 32615 |
| Phone | 386 462 6800 |
| Web | https://www.axogeninc.com |
Axogen Management Efficiency
The company has return on total asset (ROA) of (0.0275) % which means that it has lost $0.0275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1451) %, meaning that it created substantial loss on money invested by shareholders. Axogen's management efficiency ratios could be used to measure how well Axogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of January 2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to grow to -0.14. At this time, Axogen's Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alex Huang | Rxsight | N/A | |
| Bryan Olin | LivaNova PLC | 57 | |
| Andrew Hill | Paragon 28 | 41 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Scott Gaines | Rxsight | N/A | |
| Yuliya Aslan | Paragon 28 | N/A | |
| Michael CPA | Anika Therapeutics | 51 | |
| John Harris | Integer Holdings Corp | 65 | |
| Caroline Vaughn | Rxsight | N/A | |
| Robert JD | Paragon 28 | 58 | |
| Natalia Kozmina | LivaNova PLC | N/A | |
| Richard Glaze | CONMED | 59 | |
| Marshall MD | Artivion | 68 | |
| Deanna Wilke | LivaNova PLC | N/A | |
| Ray Garrison | Orthopediatrics Corp | N/A | |
| Florian Tyrs | Artivion | N/A | |
| Steve Everly | Rxsight | N/A | |
| Sarah Oliker | CONMED | 43 | |
| Robert Thomson | Artivion | 55 | |
| Nikolas Kerr | Si Bone | 53 | |
| Aimee Einstein | Si Bone | N/A | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0275 |
Axogen Inc Leadership Team
Elected by the shareholders, the Axogen's board of directors comprises two types of representatives: Axogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axogen. The board's role is to monitor Axogen's management team and ensure that shareholders' interests are well served. Axogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Angelo Scopelianos, Vice President - Research & Development | ||
| Gregory Davault, VP Marketing | ||
| Peter Mariani, Ex CFO | ||
| Maria Martinez, Chief Human Resource Officer | ||
| CFA CPA, Chief Officer | ||
| Erick DeVinney, Vice President of Clinical and Translational Sciences | ||
| Karen Zaderej, CEO and President and Director | ||
| Isabelle Billet, Chief Strategy and Business Development Officer | ||
| Jens Kemp, Chief Officer | ||
| Todd Puckett, Vice Operations | ||
| Craig Swandal, Vice Operations | ||
| Bradley JD, G Officer | ||
| Marc Began, General VP | ||
| Ed Joyce, Director Relations | ||
| Michael Donovan, Vice Operations | ||
| Doris Quackenbush, Vice Sales | ||
| Ivica MD, Chief Officer | ||
| Harold Tamayo, Vice Relations |
Axogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0275 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 840.44 M | ||||
| Shares Outstanding | 44.01 M | ||||
| Shares Owned By Insiders | 5.46 % | ||||
| Shares Owned By Institutions | 84.55 % | ||||
| Number Of Shares Shorted | 1.03 M | ||||
| Price To Earning | (47.07) X |
Pair Trading with Axogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axogen will appreciate offsetting losses from the drop in the long position's value.Moving against Axogen Stock
| 0.68 | CI | Cigna Corp | PairCorr |
| 0.5 | DH | Definitive Healthcare | PairCorr |
| 0.43 | VNRX | Volitionrx | PairCorr |
| 0.31 | DRIO | DarioHealth Corp | PairCorr |
The ability to find closely correlated positions to Axogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axogen Inc to buy it.
The correlation of Axogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth 0.179 | Return On Assets | Return On Equity |
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.